Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.

about

Current Perspectives on rosuvastatin.

P2860

Q36796490-F48618BA-B042-4E74-9ADF-9B3DA32918F4

P2860

Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.

Item

http://www.wikidata.org/entity/Q37953462

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Clinical experience with rosuv ...... uction of cardiovascular risk.

@en

Clinical experience with rosuv ...... uction of cardiovascular risk.

@nl

type

Item

label

Clinical experience with rosuv ...... uction of cardiovascular risk.

@en

Clinical experience with rosuv ...... uction of cardiovascular risk.

@nl

prefLabel

Clinical experience with rosuv ...... uction of cardiovascular risk.

@en

Clinical experience with rosuv ...... uction of cardiovascular risk.

@nl

P1476

Clinical experience with rosuv ...... uction of cardiovascular risk.

@en

P2093

Kiyoko Uno

http://www.w3.org/2001/XMLSchema#string

Stephen J Nicholls

http://www.w3.org/2001/XMLSchema#string

Yu Kataoka

http://www.w3.org/2001/XMLSchema#string

P2860

Structural mechanism for statin inhibition of HMG-CoA reductase

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

P304

1383-1390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERC.11.145

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22059787

http://www.w3.org/2001/XMLSchema#string

P921

hyperlipidemia

Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.

about

P2860

P2860

Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921